Carcinoma, Non-Small-Cell LungPhase 3AVANANCT02810457
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
A Phase 3 study testing FKB238 (bevacizumab), Avastin (bevacizumab) and Paclitaxel in people with Carcinoma, Non-Small-Cell Lung, run by Centus Biotherapeutics Limited at 147 sites in 24 countries.
Trial summary
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinoma, Non-Small-Cell Lung
- What is being tested?
- FKB238 (bevacizumab), Avastin (bevacizumab) and Paclitaxel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 731 participants
- Where
- 147 sitesin 24 countries
- Study dates
- 7 Sep 2016to 26 Jan 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 18 years or older
- Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had not received any systemic anti-cancer therapy for metastatic disease
- Histologically or cytologically confirmed diagnosis of predominantly non-squamous NSCLC
- Existence of at least 1 measurable lesion by RECIST v1.1
- Adequate hematological, renal and liver function
- Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1
- Life expectancy longer than 6 months
Who cannot join
- Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature
- Any unresolved toxicities from prior systemic therapy
- Known sensitizing epidermal growth factor receptor (EGFR) mutations or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation positive mutations
- Previous dosing with vascular endothelial growth factor (VEGF) inhibitor
- Known hypersensitivity to any excipients of the Investigational Products (IPs) and combination chemotherapy
- Use of prohibited concomitant medication
Show all 9Show fewer
- Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection
- Fertile men or women of childbearing potential not using adequate contraception.
- Other inclusion/exclusion criteria may apply.
Trial locations and contacts
147 sites in 24 countries.
147 sites in 24 countries
Russia27 sites
Research Site 6209
Arkhangelsk, Arkhangelskaya oblast, 163045
Research Site 6221
Belgorod, Belgorod Oblast, 308010
Research Site 6211
Chelyabinsk, Chelyabinsk Oblast, 454087
Research Site 6229
Izhevsk, Udmurtiya Republic, 426009
Research Site 6228
Kursk, 305035
Research Site 6217
Kuzmolovskiy, Leningradskaya Oblast', 188663
Research Site 6207
Magnitogorsk, 455001
Research Site 6225
Moscow, Moscow, 105229
Research Site 6203
Moscow, Moscow, 143423
Research Site 6230
Novgorod, Nizhny Novgorod Oblast, 603109
Research Site 6214
Novosibirsk, Novosibirsk Oblast, 630007
Research Site 6213
Novosibirsk, Novosibirsk Oblast, 630047
Research Site 6215
Omsk, Omsk Oblast, 644013
Research Site 6224
Omsk, Omsk Oblast, 644013
Research Site 6208
Orenburg, Orenburg Oblast, 460021
Research Site 6223
Rostov-on-Don, Rostov Oblast, 344037
Research Site 6205
Ryazan, Ryazan Oblast, 390011
Research Site 6235
Saint Petersburg, Sankt-Peterburg, 195271
Research Site 6212
Saint Petersburg, Sankt-Peterburg, 197022
Research Site 6216
Saint Petersburg, Sankt-Peterburg, 197342
Research Site 6202
Saint Petersburg, Sankt-Peterburg, 197758
Research Site 6210
Saint Petersburg, Sankt-Peterburg, 197758
Research Site 6201
Saint Petersburg, Sankt-Peterburg, 198255
Research Site 6222
Saint Petersburg, 198255
Research Site 6234
Samara, Samara Oblast, 443031
Research Site 6219
Saransk, Mordoviya, Respublika, 430032
Research Site 6220
Ufa, Bashkortostan Republic, 450054
United States11 sites
Research Site 7805 - Hematology & Oncology Associates, Inc.
Canton, Ohio, 44708
Research Site 7801 - Gabrail Cancer Center
Canton, Ohio, 44718
Research Site 7814 - Compassionate Care Research Group
Fountain Valley, California, 92708
Research Site 7809 - Millennium Oncology
Houston, Texas, 77090
Research Site 7803 - 21st Century Oncology
Jacksonville, Florida, 32204
Research Site 7812 - Joliet Oncology-Hematology Associates, Ltd.
Joliet, Illinois, 60435
Research Site 7804 - Tri-County Hematology & Oncology Associates, Inc.
Massillon, Ohio, 44646
Research Site 7813 - Trinity Cancer Care Center
Minot, North Dakota, 58701
Research Site 7806 - Vista Oncology Inc. PS
Olympia, Washington, 98502
Research Site 7810 - Edward H. Kaplan, MD and Associates
Skokie, Illinois, 60076
Research Site 7811 - Innovative Clinical Research Institute
Whittier, California, 90603
Ukraine10 sites
Research Site 7702
Chernivtsi, Chernivtsi Oblast, 58013
Research Site 7709
Dnipro, 49102
Research Site 7701
Ivano-Frankivsk, 76018
Research Site 7705
Kharkiv, Kharkiv Oblast, 61070
Research Site 7708
Kryvyi Rih, 50048
Research Site 7704
Kyiv, 03115
Research Site 7713
Lutsk, Volyn Oblast, 63000
Research Site 7706
Odesa, Odesa Oblast, 65055
Research Site 7710
Sumy, 40022
Research Site 7707
Uzhhorod, Zakarpattia Oblast, 88000
Spain8 sites
Research Site 7004
A Coruña, A Coruña, 15009
Research Site 7001
Burgos, 9006
Research Site 7002
Castellon, Castellon, 12002
Research Site 7005
Córdoba, Córdoba, 14004
Research Site 7009
Jaén, Jaén, 23007
Research Site 7007
Madrid, 28040
Research Site 7008
Murcia, 30008
Research Site 7003
Murcia, 30120
Poland7 sites
Research Site 5711
Brzozów, 36-200
Research Site 5702
Elblag, Warmian-Masurian Voivodeship, 82-300
Research Site 5701
Krakow, Lesser Poland Voivodeship, 31-826
Research Site 5708
Lodz, Lódzkie, 93-513
Research Site 5703
Nowy Sącz, 33-300
Research Site 5706
Olsztyn, Warmian-Masurian Voivodeship, 10-357
Research Site 5705
Toruniak, Kuyavian-Pomeranian Voivodeship, 87-100
Romania7 sites
Research Site 6101
Baia Mare, 430031
Research Site 6105
Cluj-Napoca, Cluj, 400058
Research Site 6106
Cluj-Napoca, Cluj, 400352
Research Site 6102
Constanța, 900591
Research Site 6103
Craiova, 200385
Research Site 6108
Floreşti, Cluj, 407280
Research Site 6107
Iași, 700106
Thailand7 sites
Research Site 7506
Bangkok, Bangkok, 10330
Research Site 7504
Bangkok
Research Site 7507
Chiang Mai, 50200
Research Site 7505
Chiang Rai, 57000
Research Site 7501
Hat Yai, Changwat Songkhla, 90110
Research Site 7503
Khon Kaen, 40000
Research Site 7502
Udon Thani, 41330
Belarus6 sites
Research Site 8507
Brest, Brest Oblast, 224027
Research Site 8505
Grodno, Hrodzenskaya Voblasts, 230017
Research Site 8501
Lyasny, Minsk Oblast, 223040
Research Site 8504
Minsk, Minsk Oblast, 220013
Research Site 8502
Mogilev, Mogilyov Oblast, 212018
Research Site 8506
Vitebsk, Vitebsk Oblast, 210603
Bosnia and Herzegovina6 sites
Research Site 8606
Banja Luka, 78000
Research Site 8602
Mostar, 88000
Research Site 8601
Sarajevo, 71000
Research Site 8603
Sarajevo, 71000
Research Site 8605
Tuzla, Tuzlanski Kanton, 75000
Research Site 8604
Zenica, 72000
Hungary6 sites
Research Site 3305
Budapest, 1121
Research Site 3304
Budapest
Research Site 3302
Deszk, Csongrád megye, 6772
Research Site 3303
Gyula, Bekes County, 5700
Research Site 3301
Mátraháza, Heves County, 3233
Research Site 3306
Zalaegerszeg, 8900
Philippines6 sites
Research Site 5505
Cebu City, Cebu, 6000
Research Site 5504
Makati City, National Capital Region, 1229
Research Site 5501
Manila, National Capital Region, 1000
Research Site 5502
Manila, National Capital Region, 1000
Research Site 5506
Manila, National Capital Region, 1000
Research Site 5503
Quezon, 1112
Serbia6 sites
Research Site 6402
Belgrade, 11000
Research Site 6403
Belgrade, 11000
Research Site 6404
Belgrade, 11000
Research Site 6405
Belgrade, 11070
Research Site 6401
Kamenitz, Vojvodina, 21204
Research Site 6406
Kragujevac, Šumadijski Okrug, 34000
Georgia5 sites
Research Site 2504
Batumi, Adjara, 6010
Research Site 2507
Kutaisi, Imereti, 4600
Research Site 2503
Tbilisi, 0112
Research Site 2505
Tbilisi, 0159
Research Site 2508
Tbilisi, 0186
Peru4 sites
Research Site 5402
Arequipa, 054
Research Site 5404
Arequipa, 054
Research Site 5401
Lima, 27
Research Site 5405
Lima, 41
South Korea4 sites
Research Site 6005
Busan, Busan Gwang'yeogsi, 49241
Research Site 6002
Seoul, Seoul Teugbyeolsi, 06973
Research Site 6004
Suwon, Gyeonggido, 16247
Research Site 6003
Ulsan, Ulsan Gwang'yeogsi, 44033
Taiwan4 sites
Research Site 7403
Changhua, 500
Research Site 7404
Douliu, Yunlin, 64041
Research Site 7402
New Taipei City, Taipei, 231
Research Site 7401
Taipei, 10449
Turkey (Türkiye)4 sites
Research Site 7607
Ankara, 06590
Research Site 7605
Izmir, 35100
Research Site 7601
Izmir, 35110
Research Site 7606
Malatya, 44100
Croatia3 sites
Research Site 1801
Osijek, Osjecko-baranjska Županija, 31 000
Research Site 1802
Zagreb, City of Zagreb, 10 000
Research Site 1803
Zagreb, City of Zagreb, 10 000
Germany3 sites
Research Site 2604
Hamburg, 22081
Research Site 2603
Kiel, Schleswig-Holstein, 24105
Research Site 2605
Würselen, North Rhine-Westphalia, 52146
Greece3 sites
Research Site 3004
Athens, 11527
Research Site 3003
Thessaloniki, 56403
Research Site 3005
Thessaloniki, 57010
Japan3 sites
Research Site 4301
Fukuyama-shi, Hiroshima
Research Site 4304
Kumamoto, Kumamoto
Research Site 4303
Sasebo-shi, Nagasaki
Vietnam3 sites
Research Site 8401
Hanoi, Ha Noi, Thu Do, 10000
Research Site 8402
Hanoi, Ha Noi, Thu Do, 10000
Research Site 8405
Hanoi, Ha Noi, Thu Do, 10000
Bulgaria2 sites
Research Site 0905
Sofia, Dobrich, 9300
Research Site 0904
Varna, 9010
Italy2 sites
Research Site 4107
Catania, 95126
Research Site 4106
Piacenza, 29100
About this study
Official title: A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Being tested
- FKB238 (bevacizumab), Avastin (bevacizumab), Paclitaxel, Carboplatin
- Keywords
- Cancer, Bevacizumab, Carboplatin, Paclitaxel
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FKB238 (bevacizumab)Drug
Avastin (bevacizumab)Drug
PaclitaxelDrug
CarboplatinDrug
| Study group | Role | What they receive |
|---|---|---|
| FKB238 / paclitaxel / carboplatin | Experimental | Drug: FKB238:
15 mg/kg IV infusion on Day 1 of each 21-day cycle.
Drug: Paclitaxel:
200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.
Drug: Carboplatin:
Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles. Receives: Drug: FKB238 (bevacizumab); Drug: Paclitaxel; Drug: Carboplatin |
| Avastin / paclitaxel / carboplatin | Active comparator | Drug: Avastin:
15 mg/kg IV infusion on Day 1 of each 21-day cycle.
Drug: Paclitaxel:
200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.
Drug: Carboplatin:
AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles. Receives: Drug: Avastin (bevacizumab); Drug: Paclitaxel; Drug: Carboplatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Response Rate (ORR) Assessed as the Proportion of Patients With a Best Overall Response (BOR) of Either Complete Response (CR) or Partial Response (PR)
The primary variable in this study was ORR, defined as the proportion of patients with a BOR of CR or PR (by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)). A BOR was defined as the best response (in the order of CR, PR, stable disease (SD), no evidence of disease (NED), progressive disease (PD), and not evaluable (NE)) among all post-baseline disease assessments that occurred until progression, or last evaluable assessment in the absence of progression prior to the initiation of subsequent anti-cancer therapy, irrespective of whether or not patients discontinued the study treatment. The 95% Pearson-Clopper confidence interval (CI) of ORR for each treatment arm was provided. Per RECIST v1.1 for target lesions and assessed by computed tomography (CT) or, if contraindicated, magnetic resonance imaging (MRI): CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions. Overall Response=CR+PR.
Measured: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Secondary outcomes (5)
ORR at Week 19
ORR (by RECIST v1.1) at Week 19 was defined as the proportion of patients with a BOR of CR or PR assessed at Week 19. Only tumor assessments performed up until 19 weeks (i.e. Week 18 assessment + 7 day assessment window) from randomization were considered in this analysis. Per RECIST v1.1 for target lesions and assessed by CT or, if contraindicated, MRI: CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions. Overall Response=CR+PR.
Measured: From the date of randomization up to Week 19.
Progression-free Survival (PFS)
The event of interest for PFS was defined as the interval from the date of randomization until first documented disease progression or death from any cause, whichever occurs first. Disease progression was based on tumor assessments according to RECIST v1.1 criteria. The items of the overall response CR, PR, SD and NED were taken as progression-free whereas PD denoted disease progression. PFS was summarized using Kaplan-Meier estimates of the quartiles for each treatment arm, and 95% CIs for the medians were calculated. Per RECIST v1.1 for target lesions and assessed by CT or, if contraindicated, MRI: PD=at least a 20% increase in the sum of the longest diameter of target lesions, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.
Measured: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Overall Survival (OS)
The event of interest was defined as death from any cause. OS was defined as the interval from date of randomization until the date of death due to any cause. OS was summarized using Kaplan-Meier estimates of the quartiles for each treatment arm, and 95% CIs for the medians were calculated.
Measured: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Duration Of Response (DOR)
DOR was evaluated in this study as a secondary efficacy endpoint. Only the patients defined as responders in the primary analysis of ORR were taken into account for the analysis of DOR. The event of interest was defined as first documented disease progression or death due to any reason, whichever occurred first. DOR was defined as the interval from the first documented response (as defined per RECIST v1.1) until the earlier date of the first documented disease progression or death due to any reason. The date of first documented response was taken as the date of the first tumor assessment with an overall visit response of CR or PR. Per RECIST v1.1 for target lesions and assessed by CT or, if contraindicated, MRI: CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions. DOR was calculated in units of months.
Measured: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Disease Control Rate (DCR) Assessed as the Proportion of Patients With a BOR of Either CR, PR, SD or NED
The DCR was defined as the proportion of patients defined as responders. The number and percentage of responders and non-responders and the 95% Pearson-Clopper CI of DCR for each treatment arm was provided. The odds ratio for treatment (FKB238 arm versus Avastin arm) and the corresponding 95% Wald CI were produced based on a logistic regression analysis of DCR. Per RECIST v1.1 for target lesions and assessed by CT or, if contraindicated, MRI: CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions; SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. DCR=CR+PR+SD (≥ 6 weeks).
Measured: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2016 (estimated)
- Study start7 Sep 2016
- Primary completion24 Jan 2019
- Study completion26 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Carcinoma, Non-Small-Cell LungStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 731 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centus Biotherapeutics Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Centus Biotherapeutics Limited, Study director, Centus Biotherapeutics Limited
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02810457
- Sponsor's protocol ID
- FKB238-002
- Other IDs
- 2015-004104-33, 2015
- Acronym
- AVANA
- Status last verified
- Feb 2022
- First submitted
- 3 Jun 2016
- Last updated
- 10 Mar 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Syrigos K, Abert I, Andric Z, Bondarenko IN, Dvorkin M, Galic K, Galiulin R, Kuchava V, Sriuranpong V, Trukhin D, Zhavrid E, Fu D, Kassalow LM, Jones S, Bashir Z; AVANA Investigators. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). BioDrugs. 2021 Jul;35(4):417-428. doi: 10.1007/s40259-021-00489-4. Epub 2021 Jul 15.
PubMed 34264503
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin
- ClinicalTrials.gov ID
- NCT02810457
- Acronym / sponsor ID
- AVANA / FKB238-002
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Keywords
- Cancer, Bevacizumab, Carboplatin, Paclitaxel
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 731 participants (actual)
- Lead sponsor
- Centus Biotherapeutics LimitedIndustry (pharma, biotech, devices)
- Study start
- 7 Sep 2016 (actual)
- Primary completion
- 24 Jan 2019 (actual)
- Study completion
- 26 Jan 2022 (actual)
- First posted
- 23 Jun 2016 (estimated)
- Results
- Posted 19 Mar 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| FKB238 / paclitaxel / carboplatin | Experimental | Drug: FKB238 (bevacizumab), Drug: Paclitaxel, Drug: CarboplatinDrug: FKB238: 15 mg/kg IV infusion on Day 1 of each 21-day cycle. Drug: Paclitaxel: 200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles. Drug: Carboplatin: Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles. |
| Avastin / paclitaxel / carboplatin | Active comparator | Drug: Avastin (bevacizumab), Drug: Paclitaxel, Drug: CarboplatinDrug: Avastin: 15 mg/kg IV infusion on Day 1 of each 21-day cycle. Drug: Paclitaxel: 200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles. Drug: Carboplatin: AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients aged 18 years or older
- Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had not received any systemic anti-cancer therapy for metastatic disease
- Histologically or cytologically confirmed diagnosis of predominantly non-squamous NSCLC
- Existence of at least 1 measurable lesion by RECIST v1.1
- Adequate hematological, renal and liver function
Key exclusion criteria (9 listed)
- Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature
- Any unresolved toxicities from prior systemic therapy
- Known sensitizing epidermal growth factor receptor (EGFR) mutations or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation positive mutations
- Previous dosing with vascular endothelial growth factor (VEGF) inhibitor
- Known hypersensitivity to any excipients of the Investigational Products (IPs) and combination chemotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FKB238 (bevacizumab) | Drug | FKB238 / paclitaxel / carboplatin |
| Avastin (bevacizumab) | Drug | Avastin / paclitaxel / carboplatin |
| Paclitaxel | Drug | Avastin / paclitaxel / carboplatin, FKB238 / paclitaxel / carboplatin |
| Carboplatin | Drug | Avastin / paclitaxel / carboplatin, FKB238 / paclitaxel / carboplatin |
Primary outcome
Overall Response Rate (ORR) Assessed as the Proportion of Patients With a Best Overall Response (BOR) of Either Complete Response (CR) or Partial Response (PR)
Time frame: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
The primary variable in this study was ORR, defined as the proportion of patients with a BOR of CR or PR (by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)). A BOR was defined as the best response (in the order of CR, PR, stable disease (SD), no evidence of disease (NED), progressive disease (PD), and not evaluable (NE)) among all post-baseline disease assessments that occurred until progression, or last evaluable assessment in the absence of progression prior to the initiation of subsequent anti-cancer therapy, irrespective of whether or not patients discontinued the study treatment. The 95% Pearson-Clopper confidence interval (CI) of ORR for each treatment arm was provided. Per RECIST v1.1 for target lesions and assessed by computed tomography (CT) or, if contraindicated, magnetic resonance imaging (MRI): CR=disappearance of all target lesions; PR=at least 30% decrease from baseline in the sum of diameters of target lesions. Overall Response=CR+PR.
5 secondary outcomes
ORR at Week 19
Time frame: From the date of randomization up to Week 19.
Progression-free Survival (PFS)
Time frame: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Overall Survival (OS)
Time frame: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Duration Of Response (DOR)
Time frame: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Disease Control Rate (DCR) Assessed as the Proportion of Patients With a BOR of Either CR, PR, SD or NED
Time frame: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 34264503Syrigos K, Abert I, Andric Z, Bondarenko IN, Dvorkin M, Galic K, Galiulin R, Kuchava V, Sriuranpong V, Trukhin D, Zhavrid E, Fu D, Kassalow LM, Jones S, Bashir Z; AVANA Investigators. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). BioDrugs. 2021 Jul;35(4):417-428. doi: 10.1007/s40259-021-00489-4. Epub 2021 Jul 15.
Related trials for Carcinoma, Non-Small-Cell Lung
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Centus Biotherapeutics Limited study director
Centus Biotherapeutics Limited
147 sites in 24 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing FKB238 (bevacizumab), Avastin (bevacizumab) and Paclitaxel in people with Carcinoma, Non-Small-Cell Lung, run by Centus Biotherapeutics Limited at 147 sites in 24 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 147 sites in Russia, United States, Ukraine, Spain, Poland and 19 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Mar 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Response Rate (ORR) Assessed as the Proportion of Patients With a Best Overall Response (BOR) of Either Complete Response (CR) or Partial Response (PR) (time frame: Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02810457, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2022.